Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Jul 15.

Published in final edited form as: Lab Invest. 2011 Feb 14;91(4):598–608. doi: 10.1038/labinvest.2010.205

A and B. A representative of flow cytometry data showing the frequency of CD4⁺CD25⁺ T cells and CD11b⁺Gr-1⁺ cells in spleens and bone marrow from normal mice or tumor-bearing mice treated with solvent or sorafenib; C and D. A representative (C) and collective ( D, n=3) of flow cytometry data showing the expression of FOXP3 in CD4⁺CD25⁺ T cells in spleens from normal mice or tumor-bearing mice treated with solvent or sorafenib; E. A representative of flow cytomrtey data showing the frequency of CD11b⁺ Gr-1⁺cells in bone marrow (upper panel) and spleen (lower panel) from normal mice or tumor-bearing mice treated with solvent or sorafenib; F. Mean CD11b⁺ Gr-1⁺ cells frequency bone marrow and spleen from normal and HCC tumor-bearing mice treated with solvent or sorafenib (n=5) . Data represent the mean ± SD of 3 or 5 mice per group from one representative experiment of two similar experiments.

A and B. A representative of flow cytometry data showing the frequency of CD4⁺CD25⁺ T cells and CD11b⁺Gr-1⁺ cells in spleens and bone marrow from normal mice or tumor-bearing mice treated with solvent or sorafenib; C and D. A representative (C) and collective ( D, n=3) of flow cytometry data showing the expression of FOXP3 in CD4⁺CD25⁺ T cells in spleens from normal mice or tumor-bearing mice treated with solvent or sorafenib; E. A representative of flow cytomrtey data showing the frequency of CD11b⁺ Gr-1⁺cells in bone marrow (upper panel) and spleen (lower panel) from normal mice or tumor-bearing mice treated with solvent or sorafenib; F. Mean CD11b⁺ Gr-1⁺ cells frequency bone marrow and spleen from normal and HCC tumor-bearing mice treated with solvent or sorafenib (n=5) . Data represent the mean ± SD of 3 or 5 mice per group from one representative experiment of two similar experiments.